Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
26 Cards in this Set
- Front
- Back
what is the duration of the drug effect dependent on?
|
rates of absorption and elimination
|
|
what is a consequence of saturated zero-order elimination?
|
little to no metabolic reserve is available
|
|
what compounds are described by michaelis-menten kinetics?
|
phenytoin and ethanol
|
|
what describes kinetics of limiting capacity?
|
michaelis-menten kinetics
|
|
what is characteristic of first order kinetics?
|
rate depends on concentration
|
|
what describes absorption of drug solutions and elimination of most drugs at therpeutic doses?
|
first order kinetics
|
|
how is bioavailability calculated?
|
AUC values for oral relative to IV or relative bioavailability of product X versus product Y
|
|
why are drugs that are acids or bases often provided as pharmaceutical salts?
|
salt forms are more stable for storage and more soluble for absorption
|
|
does clearance of a drug change as concentration drops?
|
clearance is independent of drug concentration and remains constant with first-order changes in plasma levels
|
|
which takes longer to reach steady state, a drug with a short or long half life?
|
long half life reach steady state slowly
|
|
what are disadvantages of a loading dose?
|
high transient blood levels producing toxicity, no similar means to remove drug once given
|
|
what is a rule of thumb for dosing intervals?
|
use of dosing intervals equal to the half-life of the drug will result in a two-fold concentration fluctuation (maximum level equals twice the minimum)
|
|
when is blood drug level monitoring useful?
|
drug response is difficult to quantify, small therapeutic window, response inadequately predicted from dose due to variability in blood concentrations in the population, relationship between concentration and effect must be known
|
|
why blood drug concentration monitoring rather than use dose-response relationships?
|
when drug response is difficult to monitor directly, concentration-response relationships usually are less variable
|
|
where is variability generated in looking at dose-response relationships?
|
differences in absorption, distribution, metabolism, excretion
|
|
what are indications for serum concentration measurements?
|
evaluate concentration-related toxicity, analyze lack of therapeutic efficacy, ensure dose regimen is adequate, use pharmacokinetics to guide dose adjustments
|
|
what could cause concentration-related toxicity?
|
unexpectedly slow drug elimination, overdose, surreptitious drug use, dispensing errors
|
|
what could cause lack of therapeutic efficacy?
|
noncompliance, poor absorption or bioavailability, unexpectedly rapid drug elimination
|
|
what are important factors in interpreting blood drug levels?
|
timing with respect to time of drug administration, patient physiological state, presence of active metabolites
|
|
for what drugs is concentration monitoring useful?
|
psychotropic drugs, digoxin, anti-arrhythmics, anti-seizure, aminoglycosides, immunosuppressive anti-rejection drugs
|
|
psychotropic drugs for which concentration monitoring is useful?
|
lithium; antidepressants: amitriptyline/nortiptyline, imipramine/desipramine, doxepin/nordoxepin
|
|
anti-arrhythmic drugs for which concentration monitoring is useful?
|
lidocaine, procainamide, and N-acetylprocainamide (active metabolite)
|
|
anti-seizure drugs for which concentration monitoring is useful?
|
phenytoin, carbamazepine, primidone and metabolic phenobarbital (active metabolite)
|
|
aminoglycoside antibacterial drugs for which concentration monitoring is useful and what is a possible consequence of toxicity?
|
amikacin and tobramycin; ototoxicity
|
|
immunosuppressive anti-rejection drugs for which concentration monitoring is useful?
|
cyclosporine, tacrolimus, sirolimus
|
|
which drugs for which concentration monitoring is useful have a active metabolite that needs to be taken into account and what is it?
|
procainamide (N-acetylprocainamide) and primidone (phenobarbital)
|